Prince William and Kate release photo of daughter Charlotte to mark ninth birthday
Prince William and his wife Kate released a picture of their daughter Charlotte to mark the princess's ninth birthday on Thursday.
For two years, Becky Mourey pushed the Food and Drug Administration to approve an experimental drug for her Lou Gehrig's disease.
She went to members of Congress and health regulators to make the case for Relyvrio, until patient-advocates finally prevailed.
In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years. But patients and physicians who celebrated Relyvrio's approval several months ago are now contending with the obstacles posed by the U.S. health-care system.
Their odyssey is an object lesson in the soaring cost of specialty drugs and the byzantine systems that insurers have created to try and control them.
Patients with insurance coverage say the US$158,000 per year price tag set by drugmaker Amylyx Pharmaceutical is fueling insurance delays or denials, and sometimes exorbitant out-of-pocket expenses.
Mourey's insurer initially refused to cover Relyvrio, but reversed itself seven weeks later after online pressure-- including social media posts by Mourey and other ALS advocates.
"Amylyx priced it way too high," said Mourey, 58, a former music teacher, who now communicates using a vision-controlled speech computer. "They could cut the price in half and still make a hefty profit."
Even when Relyvrio is covered, some patients see themselves shouldering co-payments between $1,000 and $4,000 per month.
Unlike those patients, the Moureys have been exempt from copays due to a combination of company-managed Medicare and Medicaid coverage.
Some ALS patients are covered by private plans, while others receive government coverage through programs like Medicare.
In both cases, patients and their doctors can face onerous requirements to document their condition before insurers will pay for an expensive new treatment. Additionally, many insurers require patients to pay a percentage of their pharmacy costs. With many drugmakers now charging upwards of $100,000 for drugs approved for hard-to-treat illnesses, even a five per cent copay can become unaffordable. The trend has increasingly made the drug industry deeply unpopular in the U.S.
Drugmakers say their prices reflect the years of costly clinical trials needed to win FDA approval.
Amylyx said the delays in coverage for Relyvrio are normal because many insurers are still writing their policies for the drug. The company also highlighted its multiple programs to help patients with costs, including providing the drug for free to the uninsured and covering copays for those who qualify for assistance.
The issues surrounding Relyvrio's price highlight industry practices that have long been blamed for driving up U.S. health costs: drugmakers can patent new combinations of old ingredients and then charge whatever price the market will bear.
Insurers have responded with extra review hurdles. Those delays weigh heavily on patients with ALS which is measured in the monthly loss of functions like walking, speaking and swallowing.
"It's just stressful and aggravating to get these multiple denial letters," said Jim Mourey, who cares for his wife full time at their home in Hopkinton, Massachusetts.
Relyvrio is a powder-based formulation that combines two older ingredients: a prescription drug for liver disorders and a supplement used in traditional Chinese medicine that's available on Amazon.com for about $1 per day's supply.
Insurers typically won't pay for ALS patients to receive the prescription ingredient, because it's not approved for their disease. But some patients have gotten their plans to cover it or have found lower-price versions -- for less than $600 a month-- at specialty pharmacies. That's led some patients to skip the new drug entirely by obtaining its two ingredients separately.
Analysts expect Relyvrio to generate $450 million in annual sales for Amylyx by 2024. It's the company's first product.
One group that analyzes drug pricing said a fair price for Relyvrio would be between $9,100 and $30,700 per year. The drug showed some effectiveness in slowing the progression of ALS, based on patient questionnaires. Amylyx is conducting a larger study to answer lingering questions about its effectiveness, including whether it extends survival.
Layne Oliff, 63, hasn't yet decided whether to seek coverage from his Medicare plan. Under the federal program, he would likely owe $7,400 in copays for Relyvrio before reaching his out-of-pocket maximum. That's on top of monthly administration fees of over $600.
But if he pays cash, Oliff says he can buy the prescription ingredient in the drug for $550 per month, or $6,600 per year, from a specialty pharmacy. He can get the supplement online for about $30 a month.
"You're talking about a drug that's not a cure, though it has helped slow the progression" said Oliff, who trained as a pharmacist. "But I don't want to leave my wife someday in a financial hole; I'm not going to spend all my money on this drug."
Amylyx has set up a program to cover the copay costs for patients with private insurance. But that financial assistance cannot be used for federal plans like Medicare and the Veterans Administration, which cover many ALS patients. After initially restricting coverage, the VA recently broadened its eligibility.
Other insurers are initially rejecting coverage or requiring multiple rounds of documentation from doctors.
"When someone's lifespan is measured in months, making people go through these multiple rounds of review is just cruel," said Neil Thakur of the ALS Association. The group invested in Amylyx's early research and stands to recoup that investment.
Dr. Terry Heiman-Patterson, a neurologist at Temple University, says it's taken about four to six hours of phone calls with insurers to get each new patient on Relyvrio.
Heiman-Patterson warns her patients to expect weeks of back-and-forth before getting the drug.
"This is the process we're going to have to go through and I don't know what your copay is going to be in the end,"' she says.
Some patients who are already taking a do-it-yourself approach to the treatment see little reason to change.
Sarah Nauser, a former police officer, says her insurance has covered the prescription ingredient in Relyvrio -- sodium phenylbutyrate -- for a $10 copay since 2020.
"After seeing all the difficulties that people are having, I'm not going to mess with what's working," said Nauser, 34, who credits the combination with slowing her disease and helping her to maintain her ability to walk, talk and feed herself.
The co-founders of Cambridge, Massachusetts.-based Amylyx theorize that the two chemicals in their drug work together to shield cells from premature death. But there's little agreement among scientists about how the drug works, or even which ingredient is responsible for its benefit.
A small European study of the supplement contained in Relyvrio showed a larger effect on slowing ALS than Amylyx's study. And researchers there are conducting a larger, 300-patient study of the ingredient.
"That study could be hugely important in telling us whether this one ingredient--which is very inexpensive-- is actually effective," said Diana Zuckerman of the non-profit National Center for Health Research, which analyzes medical research.
------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
Prince William and his wife Kate released a picture of their daughter Charlotte to mark the princess's ninth birthday on Thursday.
The trusted traveller program between Canada and the United States is extremely popular and almost two million Canadians have a Nexus card.
Scientists studying a Neanderthal woman's remains have painstakingly pieced together her skull from 200 bone fragments to understand what she may have looked like.
Inspections are underway at more than one Loblaws location in Ottawa after complaints were filed about tall Plexiglas barriers.
The makers of Ozempic say their weight-loss drug Wegovy will be available to patients in Canada starting Monday.
Archeologists have unearthed the skeletons of five people, missing their hands and feet, at a former Nazi military base in Poland.
A Canadian restaurant lowered its prices this week, and though news of price tags dropping rather than climbing sounds unusual, the business strategy in this case is not, according to experts in the field.
In an effort to balance the profitability of Mother's Day with the pain it causes some people, some brands are offering customers the choice to opt out of Mother's Day email advertising.
Just days before the seventh anniversary of the day Jack Letts was thrown in prison with thousands of suspected ISIS fighters, his mother, Sally Lane, delivered a small stack of envelopes to the headquarters of Global Affairs Canada in Ottawa.
A group of SaskPower workers recently received special recognition at the legislature – for their efforts in repairing one of Saskatchewan's largest power plants after it was knocked offline for months following a serious flood last summer.
A police officer on Montreal's South Shore anonymously donated a kidney that wound up drastically changing the life of a schoolteacher living on dialysis.
Since 1932, Montreal's Henri Henri has been filled to the brim with every possible kind of hat, from newsboy caps to feathered fedoras.
Police in Oak Bay, B.C., had to close a stretch of road Sunday to help an elephant seal named Emerson get safely back into the water.
Out of more than 9,000 entries from over 2,000 breweries in 50 countries, a handful of B.C. brews landed on the podium at the World Beer Cup this week.
Raneem, 10, lives with a neurological condition and liver disease and needs Cholbam, a medication, for a longer and healthier life.
The lawyer for a residential school survivor leading a proposed class-action defamation lawsuit against the Catholic Church over residential schools says the court action is a last resort.
Mounties in Nanaimo, B.C., say two late-night revellers are lucky their allegedly drunken antics weren't reported to police after security cameras captured the men trying to steal a heavy sign from a downtown business.
A property tax bill is perplexing a small townhouse community in Fergus, Ont.